Business
Trevi Therapeutics to Participate in Upcoming April Investor Conferences
NEW HAVEN, Conn., April 3, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the
About this update from Trevi Therapeutics, Inc.
[{"type":"text","content":"NEW HAVEN, Conn., April 3, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be participating in the following investor conferences in April.\n\n \n \n \n \n \n \n\n \n24th Annual Needham Virtual Healthcare ConferenceApril 7-10, 2025Corporate Presentation: April 7, 11:00-11:40 a.m. ETTrevi Representatives: Jennifer Good, President and CEO, and Farrell Simon, CCORegister here to watch the live presentation.\nJones Healthcare and Technology Innovation ConferenceApril 8-9, 2025, Las Vegas, NevadaCorporate Presentation: April 9, 11:00-11:20 a.m. PTTrevi Presenter: Jennifer Good, President and CEOPresentation available to in-person attendees.\nPiper Sandler Spring Biopharma SymposiumApril 16-17, 2025, Boston, MassachusettsTrevi Representatives: Jennifer Good, President and CEO, and James Cassella, CDO\nAbout Trevi Therapeutics, Inc.Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio is the first and only therapy in clinical development to show a statistically significant reduction in chronic cough across patients with both IPF and RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), which are opioid receptors that play a key role in controlling cough hypersensitivity. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency. \nChronic cough is a highly prevalent condition in IPF patients, impacting up to 85% of the IPF population. There are ~140,000 U.S. IPF patients and the impact of chronic cough is significant with patients coughing up to 1,500 times per day. This consistent cough and any associated damage may lead to worsening disease, a higher risk of progression, death, or need for lung transplant. Chronic cough also often leads to a decline in patients' social, physical, and psychological quality of life. There are no approved ...